靶向CD73 在肿瘤联合治疗中的研究进展

Advances in research of targeting CD73 in tumor combined therapy

摘要:

肿瘤微环境中一个重要的改变就是嘌呤代谢的改变，缺氧限制了能量转化，导致细胞外三磷酸腺 苷及后续腺苷的聚集，腺苷与腺苷受体结合后，抑制了免疫细胞浸润和激活。腺苷产生径路的各个分子高表 达与多种肿瘤的不良预后密切相关。在腺苷产生径路中，最关键的就是CD73，其是肿瘤治疗的潜在靶点，靶 向CD73 的单克隆抗体和小分子抑制剂能够阻断肿瘤的发生、发展和转移。但是单纯阻断CD73 的作用有限， 靶向CD73 小分子抑制剂或单克隆抗体联合放化疗、免疫治疗及靶向治疗的协同作用抗肿瘤效果更明显。

Abstract:

An important change in the tumor microenvironment is the change in purine metabolism. Hypoxia limits energy conversion, leading to the accumulation of extracellular ATP and subsequent adenosine. When adenosine binds to adenosine receptor, it inhibits immune cell infiltration and activation. Existing studies have found that the high molecular expression of adenosine as a whole pathway and the poor prognosis of various tumors closely related. In the adenosine production pathway, the most critical is the ecto 5’-nucleotide ribozyme, CD73. CD73 is a potential target for tumor therapy, and monoclonal antibodies and small molecule inhibitors against CD73 can block tumorigenesis, progression and metastasis. However, the anti-tumor effect of blocking CD73 alone is limited. At present, the researches on targeting CD73 combined with chemotherapy, radiotherapy, immunotherapy and targeted therapy, have found that the synergistic effect of the combination of drugs increased therapeutic potential. In this review, we conclude current research progress in the combination of targeting CD73 and other anti-tumor methods in the treatment of cancer.